Assertio Therapeutics (ASRT) Price & Analysis

Compare

1,148 Followers

ASRT Stock Chart & Stats

$0.86

-$0.03(-3.72%)

At close: Jan 08 4:00 PM EST

$0.86

-$0.03(-3.72%)

Day’s Range― - ―

52-Week Range$0.51 - $1.16

Previous CloseN/A

Volume363.47K

Average Volume (3M)291.19K

Market Cap

$80.36M

Enterprise Value$9.14M

Total Cash (Recent Filing)$98.18M

Total Debt (Recent Filing)$45.79M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Nov 06, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding96,239,624

10 Day Avg. Volume201,487

30 Day Avg. Volume291,188

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.11

Enterprise Value/Revenue0.08

Enterprise Value/Gross Profit0.11

Enterprise Value/Ebitda-0.50

Forecast

1Y Price Target

$3.00

Price Target Upside248.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Product DevelopmentNew Data on Sympazan Real World Use Can Be Leveraged to Hone In on Ideal Patients by Prescribers, Potentially Accelerating Sales.

Revenue PerformanceAssertio's total revenue of $29.2M exceeded expectations, showcasing strong performance despite challenges.

Strategic ManagementManagement is actively seeking acquisitions and considering divesting non-core assets, potentially boosting future growth and capital.

Bears Say

Financial PerformanceThe company recorded a 2Q25 net loss of $0.17 vs. the original forecast for a net loss of only $0.10 per share.

Market CompetitionRisks include inability to obtain additional market share for ROLVEDON and Sympazan.

Sales GuidanceManagement decided to stop promotional efforts for Otrexup, which led to a lowering of the top-end of 2025 net product sales guidance.

Assertio Therapeutics News

Assertio Therapeutics Amends ROLVEDON Supply Agreement

Assertio Therapeutics ( ($ASRT) ) just unveiled an update. On October 7, 2025, Spectrum Pharmaceuticals, a subsidiary of...

5d ago

ASRT

Assertio Therapeutics’ Growth Potential Driven by Sympazan and Stable Revenue Streams

Maxim Group analyst Naz Rahman reiterated a Buy rating on Assertio Therapeutics yesterday and set a price target...

29d ago

ASRT

Buy Rating Affirmed for Assertio Therapeutics Amid Positive Sympazan Study and Strong Financial Outlook

Assertio Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

29d ago

ASRT

Assertio presents new data from study of SYMPAZAN Oral Film

Assertio (ASRT) announced new data from a first-ever real-world study of SYMPAZAN Oral Film. The data were presented...

1M ago

ASRT

Assertio Therapeutics’ Earnings Call: Mixed Sentiments and Strategic Shifts

Assertio Therapeutics (($ASRT)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

ASRT

Assertio price target lowered to $3 from $3.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Assertio (ASRT) to $3 from $3.50 and keeps a Buy...

2M ago

ASRT

Assertio Therapeutics Reports Q2 2025 Financial Results

Assertio Therapeutics ( ($ASRT) ) has released its Q2 earnings. Here is a breakdown of the information Assertio...

2M ago

ASRT

Is ASRT a Buy, Before Earnings?

Assertio Therapeutics (ASRT) is scheduled to report 2nd quarter earnings on 07/31/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

ASRT

Assertio Therapeutics: Buy Rating Affirmed Amid Strong ROLVEDON Growth and Positive Financial Outlook

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Assertio Therapeutics (ASRT – Research Report) and...

5M ago

ASRT

Assertio Therapeutics’ Earnings Call: Mixed Results and Strategic Plans

Assertio Therapeutics (($ASRT)) has held its Q1 earnings call. Read on for the main highlights of the call....

5M ago

ASRT

Assertio Therapeutics Approves Key Proposals at Annual Meeting

Assertio Therapeutics ( ($ASRT) ) has shared an announcement. At its recent Annual Meeting, Assertio Therapeutics‘ stockholders approved...

5M ago

ASRT

Assertio price target lowered to $1.50 from $1.75 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Assertio (ASRT) to $1.50 from $1.75 and keeps a...

5M ago

ASRT

Assertio Therapeutics Reports Q1 2025 Financial Results

Assertio Therapeutics ( ($ASRT) ) has released its Q1 earnings. Here is a breakdown of the information Assertio...

5M ago

ASRT

Assertio Holdings price target lowered to $3.50 from $4 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Assertio Holdings (ASRT) to $3.50 from $4 and keeps a...

7M ago

ASRT

ASRT FAQ

What was Assertio Therapeutics Inc’s price range in the past 12 months?

Assertio Therapeutics Inc lowest stock price was $0.51 and its highest was $1.16 in the past 12 months.

What is Assertio Therapeutics Inc’s market cap?

Assertio Therapeutics Inc’s market cap is $80.36M.

When is Assertio Therapeutics Inc’s upcoming earnings report date?

Assertio Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 22 days.

How were Assertio Therapeutics Inc’s earnings last quarter?

Assertio Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.08.

Is Assertio Therapeutics Inc overvalued?

According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Assertio Therapeutics Inc pay dividends?

Assertio Therapeutics Inc does not currently pay dividends.

What is Assertio Therapeutics Inc’s EPS estimate?

Assertio Therapeutics Inc’s EPS estimate is -0.09.

How many shares outstanding does Assertio Therapeutics Inc have?

Assertio Therapeutics Inc has 96,239,624 shares outstanding.

What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?

Assertio Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 13.889%.

Which hedge fund is a major shareholder of Assertio Therapeutics Inc?

Currently, no hedge funds are holding shares in ASRT

Assertio Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-38.40%

Trailing 12-Months

Asset Growth

-2.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Assertio Therapeutics Inc

Assertio Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in pain management and other therapeutic areas. The company's portfolio includes products that leverage its expertise in drug delivery and formulation technologies, with a strong emphasis on prescription medications that provide effective solutions for patients suffering from various conditions.

Assertio Therapeutics (ASRT) Earnings & Revenues

Historic Earnings Reports

ASRT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a mix of positive developments such as strong demand for Rolvedon and successful legal settlements, but also faced challenges including a decline in net product sales and the discontinuation of Otrexup commercialization. The company's financial position remains strong, which supports future strategic transactions.View all ASRT earnings summaries

ASRT Stock 12 Month Forecast

Average Price Target

$3.00

▲(248.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.79,0.96,1.13,1.3,1.47,1.64,1.81,1.98,2.15,2.32,2.4899999999999998,2.66,2.83,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.79,0.96,1.13,1.3,1.47,1.64,1.81,1.98,2.15,2.32,2.4899999999999998,2.66,2.83,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.79,0.96,1.13,1.3,1.47,1.64,1.81,1.98,2.15,2.32,2.4899999999999998,2.66,2.83,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.88,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >